• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MetaVia Inc. filed SEC Form 8-K: Leadership Update

    1/27/26 4:01:21 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    METAVIA INC._January 23, 2026
    0001638287false00016382872026-01-232026-01-23

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): January 23, 2026

    Graphic

    METAVIA INC.

    (Exact name of Registrant as Specified in Its Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

    ​

    001-37809

    ​

    47-2389984

    (State or other jurisdiction

    of incorporation)

    ​

    (Commission

    File Number)

    ​

    (IRS Employer

    Identification No.)

    ​

    ​

    ​

    ​

    ​

    ​

    545 Concord Avenue, Suite 210

    Cambridge, Massachusetts

    ​

    ​

    02138

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (857) 702-9600

    (Registrant’s telephone number, including area code)

    ​

    Not applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Title of each class

      ​ ​ ​

    Trading

    Symbol(s)

      ​ ​ ​

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    MTVA

     

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On January 5, 2026, MetaVia Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-292581) with the Securities and Exchange Commission (as amended, the “Registration Statement”). Pursuant to Instruction 1 to Item 402(c)(2)(iii) and (iv) of Regulation S-K, the “Summary Compensation Table for 2025 and 2024” included in the Registration Statement noted that the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) had not yet determined the amount of discretionary cash bonuses payable to the Company’s principal executive officer and up to two of the most highly compensated executive officers other than the principal executive officer (the “Named Executive Officers”) for the fiscal year ended December 31, 2025 (“Fiscal Year 2025”), and that the amounts of such discretionary cash bonuses would be disclosed in a Current Report on Form 8-K under Item 5.02(f) once the amounts are determined.

     

    On January 23, 2026, the Compensation Committee approved discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated “Summary Compensation Table for 2025 and 2024”, which includes the amount of discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025, as well as the total compensation figures for the Company’s Named Executive Officers for Fiscal Year 2025.

    ​

    Summary Compensation Table for 2025 and 2024

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    (1)​

    ​

    ​

    ​

    Name and Principal Position

    ​

    ​

    Year

    ​

    ​

    ​

    Salary

    ($)

    ​

    ​

    Bonus

    ($)

    ​

    ​

    Stock

    Awards

    ($)

    ​

    ​

    All Other

    Compensation

    ($)(1)

    ​

    ​

    Total

    ($)

    Hyung Heon Kim, President and Chief Executive Officer

    ​

    ​

    2025

    ​

    ​

    ​

    479,723

    ​

    ​

    239,862

    ​

    ​

    —

    ​

    ​

    36,743

    ​

    ​

    756,328

     

    ​

    ​

    2024

    ​

    ​

    ​

    460,125

    ​

    ​

    220,163

    ​

    ​

    —

    ​

    ​

    36,116

    ​

    ​

    716,404

    Marshall H. Woodworth, Chief Financial Officer

    ​

    ​

    2025

    ​

    ​

    ​

    393,300

    ​

    ​

    157,320

    ​

    ​

    —

    ​

    ​

    12,365

    ​

    ​

    562,985

     

    ​

    ​

    2024

    ​

    ​

    ​

    316,667

    ​

    ​

    120,663

    ​

    ​

    209,015

    ​

    ​

    128,354

    ​

    ​

    774,699

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    (1) “All Other Compensation” for Fiscal Year 2025 was related to health and welfare benefits paid by MetaVia.

    ​

    ​

    ​

    ​

    Signatures

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

      ​ ​ ​

    METAVIA INC.

    ​

    ​

    ​

    ​

    ​

    ​

    Date: January 27, 2025

    ​

    By:

    /s/ Hyung Heon Kim

    ​

    ​

    ​

    Hyung Heon Kim

    ​

    ​

    ​

    President and Chief Executive Officer

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    9/4/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H was granted 28,000 shares, increasing direct ownership by 1,024% to 30,734 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:02:10 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Kim Hyung Heon was granted 32,000 shares, increasing direct ownership by 577% to 37,545 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:01:16 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Woodworth Marshall H gifted 14,200 shares, decreasing direct ownership by 32% to 30,079 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    8/13/25 4:36:41 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    SEC Filings

    View All

    MetaVia Inc. filed SEC Form 8-K: Leadership Update

    8-K - MetaVia Inc. (0001638287) (Filer)

    1/27/26 4:01:21 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    1/16/26 4:05:21 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by MetaVia Inc.

    424B4 - MetaVia Inc. (0001638287) (Filer)

    1/16/26 8:36:51 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/4/25 4:01:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    5/20/25 4:16:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

    CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants.

    1/16/26 4:01:00 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

    CAMBRIDGE, Mass., Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and Series C Warrants and Series D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants. The underwritten public

    1/15/26 9:32:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

    Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic Response with a 12.3 mg/dL Fasted Glucose Reduction by Day 54 Robust Weight Loss with 9.1% Reduction (21.2 lbs) by Day 54 CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week (extended from four weeks) non-titrated 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual ox

    1/5/26 8:30:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care